Another important milestone has been achieved, allowing the Institute for Myocardial Infarction Research to generate new data to understand the efficacy and safety of cangrelor in high-risk patients.
All news of the category Projects
The ethics committee approved the observational monitoring design for the CAN-SHOCK registry with no further conditions.
First patient enrolled in the REBOOT PARADOX clinical trial at Ludwigs-Maximilians-University Munich.
Having received a positive vote from the ethics committee is great because it means that we can get started with the study straight away.
The analysis of the Year 1 data has confirmed that the ‘culprit lesion only’ strategy provides significant advantages over multivessel revascularisation.